Development of Monoclonal anti-A Production of National Blood Centre, Thai Red Cross Society

บทคัดย่อ

Abstract:

The objective of this study is to develop anti-A by using hybridoma technique. The mouse
myeloma  cells (653) and spleen cells from Balb/C were immunized with 20% A cells, obtaining clone
3C4  secreting monoclonal anti-A mixture. Reaction comparison using old monoclonal anti-A (NBC),
and  commercial monoclonal anti-A in terms of potency, specificity, avidity and stability were established.
It was found that new monoclonal anti-A (3C4) was better than the old monoclonal anti-A
(NBC)  and was competitive with commercial monoclonal anti-A in terms of efficacy of avidity about
1-2  second, and 100% in specificity. It was no significant difference with A1, A2, A1B and A2B cells
test  in avidity. The results showed positive to A1, A2, A3, A1B, A2B and A3B cells test but negative to
blood  group B and blood group O test.  Inclusively, the manufacturing cost was lower than that of
monoclonal  anti-A (NBC) of about 26.49 percent, and monoclonal anti-A (3C4) reagent is stable for over
18  month at 4 ํ C. Therefore, the products could be utilized as a routine use in blood group testing.